{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T07:02:58Z","timestamp":1760425378489},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["psy-journal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.psychres.2015.11.041","type":"journal-article","created":{"date-parts":[[2015,11,24]],"date-time":"2015-11-24T11:02:30Z","timestamp":1448362950000},"page":"104-109","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Prolactin monitoring in the acute psychiatry setting"],"prefix":"10.1016","volume":"235","author":[{"given":"Benjamin I.","family":"Perry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie J.","family":"Goldring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharmila J.","family":"Menon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2015.11.041_bib2","first-page":"1075","article-title":"Guidelines for the diagnosis and treatment of hyperprolactinemia","volume":"44","author":"Biller","year":"1999","journal-title":"J. Reprod. Med."},{"key":"10.1016\/j.psychres.2015.11.041_bib3","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.schres.2008.09.019","article-title":"Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study","volume":"107","author":"Byerly","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2015.11.041_bib4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11102-008-0107-5","article-title":"Hyperprolactinemia","volume":"11","author":"Chahal","year":"2008","journal-title":"Pituitary"},{"key":"10.1016\/j.psychres.2015.11.041_bib5","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/0269881107087373","article-title":"Current guidelines and their recommendations for prolactin monitoring in psychosis","volume":"22","author":"Citrome","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2015.11.041_bib6","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4158\/EP.6.6.425","article-title":"Risperidone-associated hyperprolactinemia","volume":"6","author":"Kearns","year":"2000","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.psychres.2015.11.041_bib7","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1743-6109.2012.02735.x","article-title":"Hormonal causes of male sexual dysfunctions and their management (hyperprolactinemia, thyroid disorders, GH disorders, and DHEA)","volume":"10","author":"Maggi","year":"2013","journal-title":"J. Sex. Med."},{"key":"10.1016\/j.psychres.2015.11.041_bib8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ecl.2007.10.013","article-title":"Hyperprolactinemia and prolactinomas","volume":"37","author":"Mancini","year":"2008","journal-title":"Endocrinol. Metab. Clin. N Am."},{"key":"10.1016\/j.psychres.2015.11.041_bib9","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1192\/bjp.184.6.503","article-title":"Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia","volume":"184","author":"Meaney","year":"2004","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.psychres.2015.11.041_bib10","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archpsyc.1974.01760160102021","article-title":"Serum prolactin levels in unmedicated schizophrenic patients","volume":"31","author":"Meltzer","year":"1974","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.psychres.2015.11.041_bib11","unstructured":"National Institute for Health and Care Excellence., 2009. Schizophrenia: Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. NICE Clinical guidelines. [Online] March 2009. [Cited: January 22, 2014.] \u3008http:\/\/publications.nice.org.uk\/schizophrenia-cg82\u3009"},{"key":"10.1016\/j.psychres.2015.11.041_bib12","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.euroneuro.2009.03.003","article-title":"Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study","volume":"19","author":"Novick","year":"2009","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.psychres.2015.11.041_bib13","first-page":"273","article-title":"A review of the adverse side effects associated with antipsychotics as related to their efficacy","volume":"26","author":"Pakpoor","year":"2014","journal-title":"Psychiatr. Danub."},{"key":"10.1016\/j.psychres.2015.11.041_bib14","first-page":"421","article-title":"The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review","volume":"28","author":"Peuskens","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.psychres.2015.11.041_bib15","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/0269881107087346","article-title":"Antipsychotics and hyperprolactinaemia: clinical recommendations","volume":"22","author":"Peveler","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2015.11.041_bib16","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1017\/S0033291713000226","article-title":"Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis","volume":"43","author":"Riecher-R\u00f6ssler","year":"2013","journal-title":"Psychol. Med."},{"key":"10.1016\/j.psychres.2015.11.041_bib17","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","volume":"123","author":"Rummel-Kluge","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2015.11.041_bib18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1192\/bjp.181.1.49","article-title":"Sexual dysfunction in patients taking conventional antipsychotic medication","volume":"181","author":"Smith","year":"2002","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.psychres.2015.11.041_bib19","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2850.2009.01472.x","article-title":"Antipsychotic-induced hyperprolactinaemia in patients with schizophrenia: considerations in relation to bone mineral density","volume":"16","author":"Stubbs","year":"2009","journal-title":"J. Psychiatr. Ment. Health Nurs."},{"key":"10.1016\/j.psychres.2015.11.041_bib20","series-title":"The maudsley prescribing guidelines in psychiatry","author":"Taylor","year":"2012"},{"key":"10.1016\/j.psychres.2015.11.041_bib21","first-page":"116","article-title":"Bone mineral density and bone turnover in hyperprolactinaemia of various origins","volume":"58","author":"Zadrozna-Sliwka","year":"2007","journal-title":"Endokrynol. Pol."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178115307174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178115307174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T09:21:24Z","timestamp":1537176084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178115307174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":20,"alternative-id":["S0165178115307174"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2015.11.041","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prolactin monitoring in the acute psychiatry setting","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2015.11.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}